ClearPoint Neuro (CLPT) Stock Price, News & Analysis

Company Overview

ClearPoint Neuro, Inc. is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision. Its proprietary SmartFrame trajectory guide offers adjustable angulation under MRI control, allowing clinicians to navigate complex cranial anatomy without the need for multiple frame placements or CT scans. The company also provides disposables, such as biopsy and ablation cannulae, to complement its core guidance platform.

Founded in 2007 as a spin-out from Brigham and Women’s Hospital, ClearPoint Neuro has secured regulatory clearances in the United States and Europe and has installed its systems in leading academic medical centers worldwide. The company’s commercial operations and clinical training programs support neurosurgeons and imaging specialists in North America, Europe and select international markets, fostering broader adoption of MRI-guided stereotactic procedures.

ClearPoint Neuro is led by a management team with deep expertise in medical devices, imaging and neurosurgery. The company continues to invest in product enhancements and clinical research partnerships, aiming to expand the range of neurological conditions that can benefit from its real-time, image-guided therapy solutions.

Key Stats

• Today's Range: $10.84 to $11.69
• 50-Day Range: $8.66 to $15.16
• 52-Week Range: $8.27 to $30.10
• Volume: 265,781 shs
• Average Volume: 721,677 shs
• Market Capitalization: $347.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Hold

ClearPoint Neuro Stock Analysis - MarketRank™

ClearPoint Neuro scored higher than 40% of companies evaluated by MarketBeat, and ranked 657th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

ClearPoint Neuro has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

ClearPoint Neuro has a consensus price target of $14.50, representing about 25.3% upside from its current price of $11.57.

Amount of Analyst Coverage

ClearPoint Neuro has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.96) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ClearPoint Neuro is -12.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ClearPoint Neuro is -12.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ClearPoint Neuro has a P/B Ratio of 11.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.68% of the float of ClearPoint Neuro has been sold short.

Short Interest Ratio / Days to Cover

ClearPoint Neuro has a short interest ratio ("days to cover") of 8.44.

Change versus previous month

Short interest in ClearPoint Neuro has recently increased by 4.96%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ClearPoint Neuro does not currently pay a dividend.

Dividend Growth

ClearPoint Neuro does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

ClearPoint Neuro has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ClearPoint Neuro this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for CLPT on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.94% of the stock of ClearPoint Neuro is held by insiders.

Percentage Held by Institutions

30.08% of the stock of ClearPoint Neuro is held by institutions.

CLPT Stock Analysis - Frequently Asked Questions

How have CLPT shares performed this year?

ClearPoint Neuro's stock was trading at $13.68 at the beginning of 2026. Since then, CLPT shares have decreased by 15.4% and is now trading at $11.57.

How were ClearPoint Neuro's earnings last quarter?

ClearPoint Neuro, Inc. (NASDAQ:CLPT) issued its quarterly earnings results on Tuesday, March, 17th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. The business had revenue of $10.41 million for the quarter, compared to analysts' expectations of $10.40 million. ClearPoint Neuro had a negative net margin of 69.08% and a negative trailing twelve-month return on equity of 122.17%.
Read the conference call transcript.

Who are ClearPoint Neuro's major shareholders?

ClearPoint Neuro's top institutional shareholders include SG Americas Securities LLC (1.24%), Bank of New York Mellon Corp (0.48%) and Hsbc Holdings PLC (0.05%). Insiders that own company stock include Joseph Burnett and Timothy T Richards.
View institutional ownership trends.

How do I buy shares of ClearPoint Neuro?

Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ClearPoint Neuro own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ClearPoint Neuro investors own include Arista Networks (ANET), NVIDIA (NVDA), CrowdStrike (CRWD), Axon Enterprise (AXON), Advanced Micro Devices (AMD), Cadence Design Systems (CDNS) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 3/17/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CLPT
• CIK: 1285550
• Web: www.clearpointneuro.com
• Phone: (949) 900-6833
• Fax: 949-900-6834
• Employees: 110
• Year Founded: 1998

Price Target and Rating

• Average Price Target for ClearPoint Neuro: $14.50
• High Price Target: $20.00
• Low Price Target: $9.00
• Potential Upside/Downside: +25.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.54 million
• Net Margins: -69.08%
• Pretax Margin: -68.93%
• Return on Equity: -122.17%
• Return on Assets: -40.69%

Debt

• Debt-to-Equity Ratio: 1.75
• Current Ratio: 5.91
• Quick Ratio: 5.13

Sales & Book Value

• Annual Sales: $36.97 million
• Price / Sales: 9.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.99 per share
• Price / Book: 11.64

Miscellaneous

• Outstanding Shares: 29,990,000
• Free Float: 27,905,000
• Market Cap: $345.63 million
• Optionable: Optionable
• Beta: 1.29